Oncology Hematology Care, Inc. - Blue Ash
Cincinnati, OH
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
Teclistamab
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 2